Insilico Biotechnology AG has opened their first subsidiary in the U.S., located in Boston, MA. The foundation of Insilico Biotechnology Corporation is the next step to develop Insilico’s business in the U.S. biopharmaceutical market and will strengthen the company’s relationship with its customers in the U.S.
 
The Boston subsidiary´s prime location within the largest biopharmaceutical hub in the U.S. provides access to a significant number of biopharmaceutical companies located within the east coast. The US market comprises about a third of the estimated $270 billion global biopharmaceutical market, and from this Insilico recognizes enormous growth opportunities for implementing its digital solutions for next generation smart biomanufacturing. 
 
In addition to developing the U.S. business, Insilico Biotechnology Corp. will provide consulting and services for existing customers. With a team of account managers and application scientists, Insilico will be able to provide direct and onsite support for our customers who use the Insilico Technology Platform for predictive biomanufacturing.
 
“Following the opening of the representative office in Singapore, the foundation of the Boston subsidiary is a strategic step to achieve our vision of serving the global biopharmaceutical market as the leading provider of predictive solutions for smart bio-factories,” said Klaus Mauch, chief executive officer, Insilico.  
 
“I am extremely happy about being able to directly contribute to our customers’ successful digital transformation with Insilico as their partner. I am absolutely positive that this is the right time and that Boston is exactly the right place,” said Brett Lepore, the newly appointed president of Insilico Biotechnology Corp.